Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.

Nature cell biology - 1 Jan 2026

Treekitkarnmongkol Warapen, Katayama Hiroshi, Sankaran Deivendran, Tai Mei-Chee, Rauth Sanchita, Chen Hanxiao, Nguyen Tristian, Hara Kieko, Thege Fredrik I, Ponnusamy Moorthy P, Batra Surinder K, Wang Huamin, Wistuba Ignacio I, Schmittgen Thomas D, Heymach John V, Kopetz Scott, Hu Tony, Yao Wantong, Maitra Anirban, Sen Subrata

Abstract excerpt

Therapeutic targeting of mutant KRAS pathways driving cancers is being actively investigated to identify feedback mechanisms responsible for the development of adaptive resistance to mutant KRAS inhibitors undergoing clinical trials. Here we report RASH3D19 as a mediator of RAS pathway activation through a positive feedback loop involving the KRAS-microRNA signalling axis. KRAS-induced miR-222 represses ETS1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feedback, Physiological

Share to Mice, Nude

Share to MicroRNAs

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41326795
DOI: 10.1038/s41556-025-01816-5
PMCID: PMC13436838

Genes

KRAS
EGFR
ETS1
GAB1
GRB2
SOS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.PMID 41326795Read ↗

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity Read ↗

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis.Semantic proximity Read ↗

A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant TumorsSemantic proximity Read ↗

Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.Semantic proximity Read ↗

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.Semantic proximity Read ↗

Selected Approaches to Disrupting Protein-Protein Interactions within the MAPK/RAS Pathway.Semantic proximity Read ↗

A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.Semantic proximity Read ↗

Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activitySemantic proximity Read ↗

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read ↗

Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.